Evidence map›Paper›PMID 39627348›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2025

Preclinical safety and effectiveness of a long-acting somatostatin analogue [

Fabrice N Njotu, Jessica Pougoue Ketchemen, Hanan Babeker, Nikita Henning, Anjong F Tikum, Emmanuel Nwangele, Alissar Monzer, Nava Hassani, Brian D Gray, Koon Y Pak and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Fabrice N NjotuDepartment of Medical Imaging, College of Medicine, University of Saskatchewan, Saskatoon, SK, S7N 0W8, Canada.
Jessica Pougoue KetchemenDepartment of Medical Imaging, College of Medicine, University of Saskatchewan, Saskatoon, SK, S7N 0W8, Canada.
Hanan BabekerDepartment of Medical Imaging, College of Medicine, University of Saskatchewan, Saskatoon, SK, S7N 0W8, Canada.
Nikita HenningDepartment of Medical Imaging, College of Medicine, University of Saskatchewan, Saskatoon, SK, S7N 0W8, Canada.
Anjong F TikumDepartment of Medical Imaging, College of Medicine, University of Saskatchewan, Saskatoon, SK, S7N 0W8, Canada.
Emmanuel NwangeleDepartment of Medical Imaging, College of Medicine, University of Saskatchewan, Saskatoon, SK, S7N 0W8, Canada.
Alissar MonzerDepartment of Medical Imaging, College of Medicine, University of Saskatchewan, Saskatoon, SK, S7N 0W8, Canada.
Nava HassaniDepartment of Medical Imaging, College of Medicine, University of Saskatchewan, Saskatoon, SK, S7N 0W8, Canada.
Brian D GrayMolecular Targeting Technologies, Inc. West Chester, West Chester, PA, 19380, USA.
Koon Y PakMolecular Targeting Technologies, Inc. West Chester, West Chester, PA, 19380, USA.
Emina E TorlakovicDepartment of Pathology and Laboratory Medicine, College of Medicine, University of Saskatchewan, 107 Wiggins Rd, Saskatoon, SK, S7N 5A2, Canada.
Maruti UppalapatiDepartment of Pathology and Laboratory Medicine, College of Medicine, University of Saskatchewan, 107 Wiggins Rd, Saskatoon, SK, S7N 5A2, Canada. Maruti.uppalapati@usask.ca.
Humphrey FongeDepartment of Medical Imaging, College of Medicine, University of Saskatchewan, Saskatoon, SK, S7N 0W8, Canada. humphrey.fonge@crchudequebec.ulaval.ca.ORCID 0000-0001-9388-6872

Funding

Molecular Targeting Technologies Inc Molecular Targeting Technologies Inc
6 · The paper itself

Abstract

purposeWe report the preclinical evaluation of potent long-acting [

methodsThe pharmacokinetic, biodistribution, and safety studies were evaluated in healthy female and/or male BALB/c mice after intravenous injections of [

resultsPharmacokinetics confirmed a prolonged clearance half-life (40.27 ± 9.23 h) while biodistribution in healthy male and female BALB/c mice was similar, with prolonged blood circulation that peaked at 6 h. Biodistribution in subcutaneous xenograft models of NCI-H524 and NCI-H727 showed consistent tumor-uptake with SSTR2-overexpression while the projected human effective doses for males and females were 61.7 and 83.7 millisievert/megabecquerel, respectively. 2 × 34 kBq of [

conclusions[

Indexed as

Lung NeoplasmsNeuroendocrine TumorsPancreatic NeoplasmsSafetySmall Cell Lung CarcinomaSomatostatinActiniumAnimalsCell Line, TumorFemaleHumansMaleMiceMice, Inbred BALB CMice, NudeRadiopharmaceuticalsActiniumActinium-225RadiopharmaceuticalsReceptors, SomatostatinSomatostatin[225Ac]Ac-EBTATEPancreatic NETSCLCSSTR2Targeted alpha therapyToxicological safety

Identifiers

PMID39627348

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.